Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report

Ruzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao · 2026

Read Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report by Ruzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597405.txt.

Description

Ruzhu Wang and co-authors report a woman with small cell lung cancer who lived one hundred six months after diagnosis, far beyond the usual course of this aggressive disease. She was sixty-four, had never smoked, and first responded partly to chemo and radiation in 2017. The cancer returned the next year and kept advancing through two further chemo regimens.

A vessel-blocking drug started in 2019 shrank the tumor. When spread to a neck lymph node was confirmed in 2020, an immune drug was added for a short course. The long control that followed such a sequence is very uncommon after several relapses. The authors discuss how blocking vessels and freeing the immune system may reinforce each other.

Catalog record

CREATORRuzhu Wang, Yishan Lu, Tianshu Yang, Yuting Zhang, Jingwen Chen, Ping Gao
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13597405

Browse the full library · About the Tower of Babel